文献速递血栓与止血

ddPCR无创产前诊断胎儿母体血小板抗原不合的新工具

A new efficient tool for non-invasive diagnosis of fetomaternal platelet antigen incompatibility.
PubMed 文献 · Br J Haematol · 2020-04-07

本研究为概念验证研究,采用ddPCR对47例疑似或曾有FNAIT病史孕妇的血浆游离DNA进行HPA-1、-3、-5、-15四个系统胎儿血小板基因分型。74%(35/47)孕妇至少一个HPA系统不合,38%(18/47)为HPA-1不合;ddPCR预测的胎儿HPA基因型在羊膜腔穿刺或分娩后全部确认。该方法快速、安全、可靠,有助于早期识别需产前管理的高危妊娠。

要点

  • ddPCR检测孕妇血浆游离DNA可无创预测胎儿HPA-1、-3、-5、-15基因型。
  • 47例中74%至少一个HPA系统不合,38%为HPA-1不合,9例存在多重不合。
  • ddPCR预测的胎儿HPA基因型在羊膜腔穿刺或分娩后全部得到确认。

核心结论

  • 基于ddPCR的孕妇血浆胎儿HPA基因分型是一种快速、安全、可靠的无创方法。

研究设计与样本

  • 概念验证研究,纳入47例疑似或曾有FNAIT病史的孕妇,采用ddPCR检测血浆游离DNA中HPA-1、-3、-5、-15四个系统的胎儿基因型。

主要发现

  • 74%(35/47)孕妇至少一个HPA系统不合,38%(18/47)为HPA-1不合,9例存在多重不合。
  • 一例HPA-15不合伴严重胎儿血小板减少发生颅内出血,提示需对HPA-1以外系统进行无创产前基因分型。
  • ddPCR预测的胎儿HPA基因型在全部FNAIT病例中经羊膜腔穿刺或分娩后确认。

关键数值与推荐

  • HPA-1、-3、-5、-15四个系统不合的检出率分别为38%(18/47)等,但原文未逐一列出其他系统比例。
  • ddPCR预测胎儿HPA基因型与羊膜腔穿刺或分娩后确认结果一致。

临床怎么用

  • 可用于早期识别FNAIT高危妊娠,指导产前管理以降低胎儿/新生儿出血风险。
  • 对HPA-1以外系统(如HPA-15)也应考虑无创产前基因分型。

局限性

  • 概念验证研究,样本量47例,需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is the consequence of platelet destruction by maternal alloantibodies against fetal human platelet antigens (HPA). This may result in intracranial haemorrhages (ICH) or even fetal death. Currently, fetal HPA genotyping is performed using invasive procedures. Here, we carried out a proof-of-concept study for non-invasive prenatal diagnosis of fetal platelet genotyping in four HPA systems (HPA-1, -3, -5 and-15) by droplet digital polymerase chain reaction (ddPCR) using cell-free DNA extracts from the plasma of 47 pregnant women with suspected, or history of, FNAIT. Results showed that 74% (35/47) of pregnant women presented incompatibility in at least one HPA system, and 38% (18/47) of cases presented HPA-1 incompatibility, including nine women with multiple incompatibilities. ICH occurred in one case of profound fetal thrombocytopenia with HPA-15 incompatibility, confirming the need for non-invasive prenatal genotyping in systems other than HPA-1. Fetal HPA genotypes predicted by ddPCR were confirmed in all FNAIT cases after amniocentesis or delivery. Fetal HPA genotyping on maternal plasma based on ddPCR is a fast, safe and reliable non-invasive method. This technique will be useful for the early identification of pregnancies at high risk of FNAIT requiring antenatal management to minimize the risk of fetal/neonatal haemorrhage.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ouzegdouh Mammasse Y, Chenet C, Drubay D, et al. A new efficient tool for non-invasive diagnosis of fetomaternal platelet antigen incompatibility. Br J Haematol. 2020. PMID: 32266719. doi:10.1111/bjh.16593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。